Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive cancer-related gene analysis reveals that active KRAS mutation is a prognostic mutation in mycosis fungoides.

Journal of dermatological science - 1 Dec 2017

Yanagi Teruki, Nishihara Hiroshi, Fujii Kyoko, Nishimura Machiko, Narahira Atsushi, Takahashi Kanae, Iwata Hiroaki, Hata Hiroo, Kitamura Shinya, Imafuku Keisuke, Shimizu Hiroshi

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to DNA Mutational Analysis
Share to Fatal Outcome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mycosis Fungoides

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Share to Skin Neoplasms

Source

Identifiers

PMID: 28754405
DOI: 10.1016/j.jdermsci.2017.07.013

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive cancer-related gene analysis reveals that active KRAS mutation is a prognostic mutation in mycosis fungoides.PMID 28754405Read ↗

Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.Semantic proximity Read ↗

Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression.Semantic proximity Read ↗

High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoidesSemantic proximity Read ↗

Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome.Semantic proximity Read ↗

Pathogenic variants of mycosis fungoides identified using next-generation sequencing.Semantic proximity Read ↗

Integrative Mutational Landscape of Mycosis Fungoides Using a National Genomics RepositorySemantic proximity Read ↗

Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathwaysSemantic proximity Read ↗

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.Semantic proximity Read ↗

Frequent Abnormalities of the P15 and P16 Genes in Mycosis Fungoides and Sezary SyndromeSemantic proximity Read ↗

Analysis of CTCL cell lines reveals important differences between mycosis fungoides/Sézary syndrome vs. HTLV-1+ leukemic cell linesSemantic proximity Read ↗

Mycosis Fungoides Is a Proliferation of Multiple Mutational Subclones.Semantic proximity Read ↗

Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.